Abstract
Changes in D2 receptors during antidepressant therapy have been reported in patients with major depressive disorder using PET/SPET. The aim of this study was to evaluate modifications in D2 receptors that might occur in patients affected by obsessive-compulsive disorder (OCD) during serotonin reuptake sites inhibitors (SSRIs). To this purpose, we measured the in vivo binding of [11C]raclopride ([11C]Rac)in the brain of a group of OCD naíve patients before and after the repeated administration of the inhibitor SSRI fluvoxamine. Eight patients with a Diagnostic and Statistical Manual of Mental Disorders IVth edition diagnosis of OCD completed the study undergoing a PET scan and a complete clinical evaluation before and during treatment with fluvoxamine. Patients have been compared also with a group of nine age-matched normal volunteers. Fluvoxamine treatment significantly improved clinical symptoms and increased [11C]Rac binding potential (BP) in the basal ganglia of OCD patients (7.5±5.2, 6.9±6.9, and 9.9±9.3% in dorsal caudate, dorsal putamen, and ventral basal ganglia, respectively; p11C]Rac BP of previously drug-naíve OCD patients. The modifications in D2 receptor availability might be secondary to fluvoxamine effects on serotoninergic activity.
| Original language | English |
|---|---|
| Pages (from-to) | 197-205 |
| Number of pages | 9 |
| Journal | Neuropsychopharmacology |
| Volume | 32 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 1 2007 |
Fingerprint
Keywords
- Antidepressant
- Dopamine receptor
- Drug naïve
- Emission tomography
- Molecular imaging
- Obsessive-compulsive disorder
ASJC Scopus subject areas
- Pharmacology
Cite this
Fluvoxamine treatment and D2 receptors : A pet study on OCD drug-naïve patients. / Moresco, Rosa Maria; Pietra, Lucia; Henin, Marta; Panzacchi, Andrea; Locatelli, Marco; Bonaldi, Lorena; Carpinelli, Assunta; Gobbo, Clara; Bellodi, Laura; Perani, Daniela; Fazio, Ferruccio.
In: Neuropsychopharmacology, Vol. 32, No. 1, 01.01.2007, p. 197-205.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Fluvoxamine treatment and D2 receptors
T2 - A pet study on OCD drug-naïve patients
AU - Moresco, Rosa Maria
AU - Pietra, Lucia
AU - Henin, Marta
AU - Panzacchi, Andrea
AU - Locatelli, Marco
AU - Bonaldi, Lorena
AU - Carpinelli, Assunta
AU - Gobbo, Clara
AU - Bellodi, Laura
AU - Perani, Daniela
AU - Fazio, Ferruccio
PY - 2007/1/1
Y1 - 2007/1/1
N2 - Changes in D2 receptors during antidepressant therapy have been reported in patients with major depressive disorder using PET/SPET. The aim of this study was to evaluate modifications in D2 receptors that might occur in patients affected by obsessive-compulsive disorder (OCD) during serotonin reuptake sites inhibitors (SSRIs). To this purpose, we measured the in vivo binding of [11C]raclopride ([11C]Rac)in the brain of a group of OCD naíve patients before and after the repeated administration of the inhibitor SSRI fluvoxamine. Eight patients with a Diagnostic and Statistical Manual of Mental Disorders IVth edition diagnosis of OCD completed the study undergoing a PET scan and a complete clinical evaluation before and during treatment with fluvoxamine. Patients have been compared also with a group of nine age-matched normal volunteers. Fluvoxamine treatment significantly improved clinical symptoms and increased [11C]Rac binding potential (BP) in the basal ganglia of OCD patients (7.5±5.2, 6.9±6.9, and 9.9±9.3% in dorsal caudate, dorsal putamen, and ventral basal ganglia, respectively; p11C]Rac BP of previously drug-naíve OCD patients. The modifications in D2 receptor availability might be secondary to fluvoxamine effects on serotoninergic activity.
AB - Changes in D2 receptors during antidepressant therapy have been reported in patients with major depressive disorder using PET/SPET. The aim of this study was to evaluate modifications in D2 receptors that might occur in patients affected by obsessive-compulsive disorder (OCD) during serotonin reuptake sites inhibitors (SSRIs). To this purpose, we measured the in vivo binding of [11C]raclopride ([11C]Rac)in the brain of a group of OCD naíve patients before and after the repeated administration of the inhibitor SSRI fluvoxamine. Eight patients with a Diagnostic and Statistical Manual of Mental Disorders IVth edition diagnosis of OCD completed the study undergoing a PET scan and a complete clinical evaluation before and during treatment with fluvoxamine. Patients have been compared also with a group of nine age-matched normal volunteers. Fluvoxamine treatment significantly improved clinical symptoms and increased [11C]Rac binding potential (BP) in the basal ganglia of OCD patients (7.5±5.2, 6.9±6.9, and 9.9±9.3% in dorsal caudate, dorsal putamen, and ventral basal ganglia, respectively; p11C]Rac BP of previously drug-naíve OCD patients. The modifications in D2 receptor availability might be secondary to fluvoxamine effects on serotoninergic activity.
KW - Antidepressant
KW - Dopamine receptor
KW - Drug naïve
KW - Emission tomography
KW - Molecular imaging
KW - Obsessive-compulsive disorder
UR - http://www.scopus.com/inward/record.url?scp=33845686605&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845686605&partnerID=8YFLogxK
U2 - 10.1038/sj.npp.1301199
DO - 10.1038/sj.npp.1301199
M3 - Article
VL - 32
SP - 197
EP - 205
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
SN - 0893-133X
IS - 1
ER -